ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) has taken remedial actions after it failed to inform the Hong Kong bourse regarding the extension of the subscription of certain wealth management products, a Tuesday Hong Kong bourse filing said.
The issue arose as the company considered an extension in the subscription as an immaterial modification instead of a new subscription under the bourse's listing rules.
The firm conducted a detailed review of its wealth management product subscription, pledged to comply with information disclosure requirements, and decided to provide training to the relevant individuals among other measures.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。